Company intelligence / Profile preview

Sellas Clinicals

New York, New York, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

SELLAS has a pivotal Phase 3 trial (REGAL) of galinpepimut-S (GPS) in acute myeloid leukemia (AML) with a positive IDMC recommendation to continue; final analysis expected by year-end 2025. SLS009, a highly selective CDK9 inhibitor, showed positive Phase 2 results in relapsed/refractory AML and is about to enter first-line clinical trials. Both programs are in late-stage development with expansion into additional hematologic and solid tumor indications.[1][7]

Therapeutic areas: HematologyOncology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Merck & Co.GenFleet Therapeutics (Shanghai)

Beyond the preview

Go deeper on Sellas Clinicals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sellas Clinicals.

Explore the full profile